Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Inclusion Criteria:

• Patients with histopathologic diagnosis of salivary gland carcinoma

• The tumor tissues were subjected to HER2/NTRK/AR/TROP-2 immunohistochemicalstaining.

• ECOG physical status 0 or 1 score in the 3 days before the firstmedication of the study treatment;

• Age 18 or older - no upper limit;

• Life expectancy is more than 3 months; ⑥Have at least onemeasurable lesion according to RECIST1.1 standards; ⑦Women ofchildbearing age must have a negative pregnancy test within 7days before the first medication, and agree to receive thenecessary contraceptive measures; ⑧The patient must have adequate liver, kidney, bone marrow,heart and lung and other organ functions: ⑨Understanding and voluntarily signing informed consent prior toperforming any research-related evaluation/operation; ⑩Ability to comply with research visit schedules and otherprogrammatic requirements.

Exclusion Criteria:

• Known hypersensitivity or delayed anaphylaxis to any agents in this trial;

• Major surgery had been performed within 4 weeks prior to the start of the studyand did not fully recover;

• Have received a live vaccine within 4 weeks before the start of the studyor plan to receive any vaccine during the study period ;

• To study the occurrence of arterial/venous thrombosis events within 6months before medication;

• Major cardiovascular diseases;

• Is suffering from uncontrolled systemic diseases, includingdiabetes, hypertension, pulmonary fibrosis, acute lungdisease, interstitial lung disease, cirrhosis, etc.;

• Is suffering from an active infection that requiressystemic treatment;

• History of active tuberculosis; ⑨ Positive humanimmunodeficiency virus (HIV) test result; ⑩Patients with chronic hepatitis B or activehepatitis C. ⑪Conditions that the investigatorbelieves will affect the safety or compliance ofthe drug therapy in this study ⑫Female/male whois pregnant or breastfeeding or who intends togive birth;